About AGE (Advanced Glycation Endproducts)
In 1912 Louis-Camille Maillard, a French Chemist,
conducted a simple experiment in his lab that turned
out to be a shortcut that created meat flavor and
aroma through heating sugar and amino acids.
This chemical reaction has thus been called Maillard
Reaction or Browning Reaction.
Following extensive researches on the Maillard Reaction across diverse
fields from food, nutrition to therapeutics, a term of
Advanced Glycation Endproducts or AGEs has been
introduced to describe the end products of Maillard
Reaction that form under normal physiological
conditions in living organisms.
AGEs accumulate with ageing in normal condition,
but this process occurs more rapidly in patients
with conditions such as diabetes and renal failure.
The accumulation of AGEs can initiate a wide range
of abnormal responses in cells and tissues such as
inappropriate expression of growth factors, alteration in
growth dynamics, accumulation of extracellular matrix,
promotion of vasoregulatory dysfunction and initiation
of death pathways.
Skin AGE's, determined in skin
tissue samples, correlate closely with early kidney, eye
and nerve disease in patients with diabetes mellitus.
Until now it has been complicated to measure tissue
AGEs in patients because existing methods are
expensive, time consuming, lack specificity, are poorly
reproducible and/or are invasive. In addition, there is
currently no gold standard for AGEs measurements.
News on AGE research
and the AGE Reader™
New Publication: Assessment of skin autofluorescence as a marker of advanced glycation end product accumulation in type 1 diabetes.
New AGE Reader 2011 Publication OBJECTIVES: The aim of the study was to compare AGE accumulation in the skin of patients with type 1 diabetes and nondiabetic population as well as to assess its association with disease duration and metabolic control. We also aimed to assess the potential usefulness of this method in the monitoring […]
DiagnOptics receives Health Canada approval for the AGE Reader.
Press Release Groningen, the Netherlands – March, 2011 DiagnOptics has received approval from Health Canada for the AGE Reader. This allows the Canadian distributor of the AGE Reader, Bescot Healthcare, to start the sale of the AGE Reader SU and CU in Canada. Health Canada reviewed the safety, effectiveness and quality of the AGE Reader […]
AGE Reader™ Technology
The AGE Reader™ is the answer to the need for measuring AGEs without the disadvantages of the existing
methods. This state of art device provides a simple non-invasive solution which allows clinicians to determine
the AGEs' level within 30 seconds.
Many advanced glycation endproducts (AGEs) have a characteristic fluorescence. Moreover, tissue fluorescence
in (invasive) biopsies has an established association with chronic complications. The AGE Reader™ is able to
easily, quickly and non-invasively measure this tissue fluorescence.
The AGE Reader™ has a light source which illuminates the tissue of interest. This light will excite fluorescent
moieties in the tissue which will emit light with another wavelength. In the used wavelength band the major
contribution in fluorescence comes from fluorescent AGEs linked mostly to collagen, but also to other proteins
and lipids. The emitted light is detected using a spectrometer. By using specific technical adaptations including
selection of specific wavelength, modulated or pulsed light sources, a more selective discrimination of specific
AGEs can be obtained.
The AGE Reader™ is Health Canada licensed to non-invasively assess the risk of cardiovascular complications in type 2 diabetes through measuring tissue accumulation of AGEs.
AGE Reader™ System
Powered by its proprietary technologies, this revolutionary device is a novel tool to researchers and clinicians and
its arrival marks the new horizon in AGEs' detection and risk assessment on cardiovascular diseases associated with